Firm Wire items are announcements made by the firms themselves. The desk confirms that the announcement was published and reproduces its factual content. It does not verify the claims in it, and publication is not an endorsement.
Neal Gerber Eisenberg says Emer Simic will join pharma patent litigation forum
Neal Gerber Eisenberg said intellectual property partner Emer Simic will join industry and in-house leaders at ACI’s second annual Forum on Pharma & Biotech Patent Litigation USA & Canada, listed for October 14–16, 2026. The firm said the featured session examines the U.S. Supreme Court’s unanimous Hikma v. Amarin decision on skinny labels.
Key points
- The firm said the session will examine the future of skinny labeling.Neal Gerber Eisenberg
- Neal Gerber Eisenberg said active inducement of patent infringement is on the agenda.Neal Gerber Eisenberg
- The firm said the discussion will address implications for branded and generic drug manufacturers.Neal Gerber Eisenberg
- Neal Gerber Eisenberg said potential effects on future pharmaceutical patent disputes are another session topic.Neal Gerber Eisenberg